Low-molecular-weight CXCR4 ligands with variable spacers
Tetsuo Narumi1, Haruo Aikawa, Tomohiro Tanaka
1Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan.
Chemmedchem
|October 23, 2012
Summary
Researchers developed small CXCR4 ligands inspired by known compounds like T140 and FC131. Zinc complexation significantly enhanced the binding affinity of these novel CXCR4 ligands.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Molecular Biology
Background:
- CXCR4 receptor antagonists are crucial for various therapeutic applications.
- Existing CXCR4 ligands, such as T140 and FC131, provide a basis for developing new agents.
- Low-molecular-weight compounds offer potential advantages in drug development.
Purpose of the Study:
- To design and synthesize novel low-molecular-weight CXCR4 ligands.
- To explore the structure-activity relationship of these compounds.
- To investigate the impact of zinc(II) complexation on ligand binding affinity.
Main Methods:
- Design and synthesis of small molecules incorporating aromatic spacers and pharmacophore groups.
- Utilized lead compounds like T140 and FC131 as structural templates.
- Incorporated various aromatic groups, cationic groups, and bis(pyridin-2-ylmethyl)amine moieties.
- Evaluated CXCR4 binding affinity and the effect of zinc(II) complexation.
Main Results:
- Several synthesized compounds exhibited significant binding affinity for CXCR4.
- The incorporation of specific aromatic spacers and pharmacophore groups influenced binding.
- Zinc(II) complexation of bis(pyridin-2-ylmethyl)amine moieties led to a remarkable enhancement in CXCR4 binding affinity.
Conclusions:
- Novel low-molecular-weight CXCR4 ligands with promising binding affinities were successfully developed.
- Aromatic spacers and pharmacophore design are critical for CXCR4 ligand potency.
- Zinc(II) complexation represents a viable strategy to significantly boost CXCR4 ligand binding affinity.
